GLP-1R agonist use is associated with a decrease in IOP, although this correlation is not statistically significant.

Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.

In comparison ... sustained weight loss of a magnitude large enough to provide clinically significant health benefits," said Dr. Gasoyan. "Having real-world data could help manage expectations ...

Finding the right solution for weight loss can feel overwhelming, especially with so many options available. While ...

A new study published in the journal JAMA Network Open found that food left in the stomach or stool left in the bowel can ...

Agents like semaglutide show promise for treatment of substance use disorders. Inaccessibility of GLP-1 agonists due to high ...

Currently, the only FDA-approved OTC weight loss drug is Alli, which uses a 60-milligram dose of orlistat versus 120 ...

Discover why Quipt, a company with strong growth potential and undervalued stock, is a compelling investment opportunity ...

Ongoing shortages of popular weight loss and diabetes drugs in the U.S. have spurred fierce competition between established ...

A broader market trend observed ever since the Fed announced its September cut rate has been the volatility in the ...

In 1970, with a degree from the medical school of the University of Copenhagen (UCPH), Professor Jens Juul Holst embarked on ...